Thirona LogoThirona announced today that it received FDA 510(k) clearance for the latest update of its AI-based LunQ clinical software.

LungQ 3.0.0 utilizes AI to automatically segment the pulmonary segments and subsegments in the internal anatomy of the lung. The analysis includes the identification of structures like lobes, segments, subsegments, airways and fissures. It analyzes the lung tissue and fissure completeness. Thirona says it supports the diagnosis and documentation of pulmonary tissue images from CT imaging.

“A clearer understanding of lung anatomy helps enable broader adoption of minimally invasive treatments for lung diseases such as COPD and lung cancer, helping save more healthy lung tissue and lung function capacity. Acting as a map for lung anatomy, LungQ helps guide bronchoscopic navigation, leveraging AI to significantly enhance the precision, accuracy, and efficiency of bronchoscopic and surgical lung interventions,” said Eva van Rikxoort, founder and CEO of Thirona. “Solutions like LungQ are helping usher in a new era of personalized treatment for lung patients, enabling clinicians all over the world to conduct more advanced, easier-to-perform and less invasive procedures with full confidence.”

Thirona first won FDA clearance for LungQ (version 1.1.0) in 2018. The latest iteration helps to guide pulmonologists through the best approach to access various locations within the lungs. It delineates pulmonary structures and offers highly accurate CT values for pulmonary tissue.

LungQ has approval for clinical use in Europe, the UK and Australia as well.